NADH 10 mg by Natrol, Inc.

POSSIBLY EFFECTIVE

• Chronic fatigue syndrome (CFS). Several small clinical studies suggest that oral NADH, taken alone or in combination with coenzyme Q10, modestly improves symptoms of CFS. Details: One small clinical study in patients with CFS shows that taking NADH 10 mg daily for 4 weeks leads to a favorable response in around 31% of patients, compared with around 8% of those taking placebo (8267). Another small clinical study in patients with CFS shows that taking NADH 5-10 mg daily for 24 months reduces symptoms by 42% when compared to baseline in the first 3 months, with symptom scores maintained for the rest of the study. These results were similar to patients receiving conventional treatment with nutritional and psychological interventions (93687). NADH has also been evaluated in combination with other ingredients. A small clinical study in patients with CFS shows that taking a specific product (ReConnect, Vitae Natural Nutrition) containing NADH 10 mg plus coenzyme Q10 100 mg twice daily for 8 weeks reduces fatigue index scores by about 6%, compared with about 3% in those taking placebo (93686). A larger clinical study also shows that taking NADH 20 mg plus coenzyme Q10 200 mg daily for 8 weeks improves some measures of fatigue, sleep quality, and quality of life when compared with baseline. No improvements in these measures were reported with placebo (107448). It is unclear if these findings are due to NADH, coenzyme Q10, or the combination.

INSUFFICIENT RELIABLE EVIDENCE to RATE

• Aging. Although there has been interest in using oral NADH for aging, there is insufficient reliable information about the clinical effects of NADH for this purpose.
• Alcohol-related liver disease. Although there has been interest in using oral NADH for alcohol-related liver disease, there is insufficient reliable information about the clinical effects of NADH for this purpose.
• Athletic performance. Although there has been interest in using oral NADH for improving athletic performance, there is insufficient reliable information about the clinical effects of NADH for this purpose.
• Cognitive function. Although there has been interest in using oral NADH for improving various measures of cognitive function, including memory and mental alertness, there is insufficient reliable information about the clinical effects of NADH for this purpose.
• Dementia. It is unclear if oral NADH is beneficial in patients with dementia. Details: A small clinical study in patients with mild to moderate dementia of the Alzheimer, vascular, or fronto-temporal type shows that taking NADH 10 mg daily for 12 weeks does not improve measures of memory, cognition, or behavioral function when compared to baseline (8275).
• Depression. Although there has been interest in using oral and parenteral NADH for depression, there is insufficient reliable information about the clinical effects of NADH for this purpose.
• Hypertension. Although there has been interest in using oral NADH for hypertension, there is insufficient reliable information about the clinical effects of NADH for this purpose.
• Jet lag. Although there has been interest in using oral NADH for jet lag, there is insufficient reliable information about the clinical effects of NADH for this purpose.
• Parkinson disease. Small, low-quality studies have yielded conflicting findings regarding the effects of oral or parenteral NADH in patients with Parkinson disease. Details: A very small, double-blind, placebo-controlled clinical trial in patients with Parkinson disease shows that administering intravenous NADH 25 mg daily for 4 days followed by intramuscular NADH 25 mg at weeks 2 and 4 does not improve Unified Parkinson Disease Rating Scale (UPDRS) scores when compared with placebo (3090). However, a large, open-label clinical study in patients with Parkinson disease shows that taking NADH 5 mg by mouth or administering intravenous NADH 12.5 mg over 30 minutes every other day for 14 days reduces disability scores by between 30% and 50% in around 19% of patients and reduces scores by between 10% and 30% in around 59% of patients when compared with baseline (3089). Also, a smaller, open-label clinical study in patients with Parkinson disease shows that administering intravenous NADH 10 mg over 30 minutes once daily for 7 days improves symptoms as measured by the UPDRS and increases the bioavailability of levodopa when compared with baseline (3086). The validity of the findings in these open-label studies is limited by a lack of placebo control. More evidence is needed to rate NADH for these uses.

(Read more about NADH)

POSSIBLY SAFE ...when used orally and appropriately. NADH has been safely used at doses up to 10 mg daily for up to 12 weeks and 20 mg daily for up to 8 weeks (8267,8275,93686,107448).

PREGNANCY AND LACTATION:
Insufficient reliable information available; avoid using.

(Read more about NADH)

(Read more about NADH)

General ...Orally, NADH seems to be well tolerated. No adverse effects have been reported in clinical research.

(Read more about NADH)